ABSTRACT
Mechanistic studies of autoimmune disorders have identified circulating T follicular helper (cTfh) cells as drivers of autoimmunity. However, the quantification of cTfh cells is not yet used in clinical practice due to the lack of age-stratified normal ranges and the unknown sensitivity and specificity of this test for autoimmunity. We enrolled 238 healthy participants and 130 patients with common and rare disorders of autoimmunity or autoinflammation. Patients with infections, active malignancy, or any history of transplantation were excluded. In 238 healthy controls, median cTfh percentages (range 4.8% – 6.2%) were comparable among age groups, sexes, races, and ethnicities, apart from a significantly lower percentages in children less than 1 year of age (median 2.1%, CI: 0.4% – 6.8, p<0.0001). Among 130 patients with over 40 immune regulatory disorders, a cTfh percentage exceeding 12% had 88% sensitivity and 94% specificity for differentiating disorders with adaptive immune cell dysregulation from those with predominantly innate cell defects. This threshold had a sensitivity of 86% and specificity of 100% for active autoimmunity and normalized with effective treatment. cTfh percentages exceeding 12% distinguish autoimmunity from autoinflammation, thereby differentiating two endotypes of immune dysregulation with overlapping symptoms and different therapies.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by Primary Immune Deficiency Treatment Consortium Pilot/Demonstration Program (CDP), Immune Deficiency Foundation (FP01029824 to BL), National Institutes of Health (5T32AI007512-35 to BL, AN), and R01DK130465 (JC).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The institutional review board of Boston Children's Hospital gave ethical approval for this work, per protocol numbers 0409-113R and P00041537.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Funding This work was supported by Primary Immune Deficiency Treatment Consortium Pilot/Demonstration Program (CDP), Immune Deficiency Foundation (FP01029824 to BL), National Institutes of Health (5T32AI007512-35 to BL, AN), and R01DK130465 (JC).
Conflict of interest: All authors declare that no conflict of interest exists.
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
Abbreviations
- AIH
- autoimmune hepatitis
- AIHA
- autoimmune hemolytic anemia
- cTfh
- circulating T follicular helper cell
- CNS
- central nervous system
- CVID
- common variable immune deficiency
- GLILD
- granulomatous lymphocytic interstitial lung disease
- ILD
- interstitial lung disease
- IRD
- immune regulatory disorder
- ITP
- immune thrombocytopenia
- JIA
- juvenile idiopathic arthritis
- sJIA
- systemic juvenile idiopathic arthritis
- SLE
- systemic lupus erythematosus
- Tfh
- T follicular helper cell
